Lotus Eye Hospital and Institute liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

7.51×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
1.22×	1.22×	1.56×	2.25×	2.83×
0.81×	0.81×	1.04×	1.74×	2.30×
1.8	1.8	2.0	2.7	3.6
2.0	2.0	4.1	7.8	9.5

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LOTUSEYE₹110.00

Lotus Eye Hospital and Institute Limited

· Pharma & Health

₹ CrorePeersGPTHEALTH GKSL SHALBY INDRAMEDCO ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹229 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	7.51
Current Ratio	2.83	2.25	1.56	1.22	1.22
Quick Ratio	2.30	1.74	1.04	0.81	0.81
Cash, Equiv & ST Investments	3.6	2.7	2.0	1.8	1.8
Working Capital	9.5	7.8	4.1	2.0	2.0

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.